This company has been marked as potentially delisted and may not be actively trading. Cytori Therapeutics (CYTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CYTX vs. FBIO, SABS, CRIS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. Cytori Therapeutics vs. Its Competitors Fortress Biotech SAB Biotherapeutics Curis Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Cytori Therapeutics (NASDAQ:CYTX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Do analysts prefer CYTX or FBIO? Fortress Biotech has a consensus price target of $21.00, indicating a potential upside of 890.57%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Cytori Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytori Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CYTX or FBIO more profitable? Fortress Biotech has a net margin of -24.84% compared to Cytori Therapeutics' net margin of -242.60%. Cytori Therapeutics' return on equity of -272.70% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Cytori Therapeutics-242.60% -272.70% -56.23% Fortress Biotech -24.84%-693.95%-27.94% Do insiders & institutionals have more ownership in CYTX or FBIO? 2.6% of Cytori Therapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 0.7% of Cytori Therapeutics shares are owned by company insiders. Comparatively, 27.9% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable valuation & earnings, CYTX or FBIO? Cytori Therapeutics has higher earnings, but lower revenue than Fortress Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytori Therapeutics$3.67M3.79-$12.63MN/AN/AFortress Biotech$57.67M1.09-$46M-$1.05-2.02 Does the media refer more to CYTX or FBIO? In the previous week, Fortress Biotech had 7 more articles in the media than Cytori Therapeutics. MarketBeat recorded 7 mentions for Fortress Biotech and 0 mentions for Cytori Therapeutics. Cytori Therapeutics' average media sentiment score of 0.00 beat Fortress Biotech's score of -0.40 indicating that Cytori Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cytori Therapeutics Neutral Fortress Biotech Neutral Which has more volatility and risk, CYTX or FBIO? Cytori Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. SummaryFortress Biotech beats Cytori Therapeutics on 9 of the 14 factors compared between the two stocks. Get Cytori Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTX vs. The Competition Export to ExcelMetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.91M$72.47M$5.75B$9.80BDividend YieldN/AN/A3.91%4.13%P/E RatioN/A10.3231.1125.06Price / Sales3.7993.82434.1399.53Price / CashN/A18.4136.7858.67Price / Book1.797.439.086.18Net Income-$12.63M-$25.86M$3.26B$265.11M Cytori Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTXCytori TherapeuticsN/A$0.63+15.8%N/A-53.8%$13.91M$3.67M0.0037Gap UpHigh Trading VolumeFBIOFortress Biotech2.3701 of 5 stars$2.01+4.7%$21.00+944.8%+14.0%$56.77M$57.67M-0.90170News CoverageEarnings ReportGap UpHigh Trading VolumeSABSSAB Biotherapeutics2.3285 of 5 stars$2.16+6.9%$11.00+409.3%-8.5%$21M$1.32M-0.54140News CoverageShort Interest ↑Analyst RevisionCRISCuris3.1946 of 5 stars$1.65+1.2%$17.00+930.3%-56.2%$20.37M$10.91M-0.3460BOLTBolt Biotherapeutics2.9789 of 5 stars$5.50-2.3%$50.00+809.1%-62.9%$10.80M$3.64M-0.1690News CoverageEarnings ReportAnalyst ForecastAMGNAmgen4.6645 of 5 stars$284.980.0%$303.76+6.6%-7.8%$153.48B$33.42B23.3028,000Trending NewsAnalyst RevisionGILDGilead Sciences4.8438 of 5 stars$120.02-0.4%$114.82-4.3%+60.4%$149.48B$28.86B23.9117,600Positive NewsAnalyst RevisionVRTXVertex Pharmaceuticals4.9486 of 5 stars$387.77+3.6%$497.10+28.2%-17.7%$96.01B$11.02B27.726,100Positive NewsREGNRegeneron Pharmaceuticals4.8319 of 5 stars$556.55+1.9%$826.91+48.6%-50.8%$57.86B$14.20B14.0315,106News CoveragePositive NewsDividend AnnouncementAnalyst ForecastAnalyst RevisionGap UpALNYAlnylam Pharmaceuticals4.2538 of 5 stars$429.93-1.2%$403.92-6.0%+67.4%$57.02B$2.46B-174.062,230Positive NewsInsider TradeBIIBBiogen4.8558 of 5 stars$128.93+0.7%$185.63+44.0%-31.4%$18.77B$9.68B12.337,605Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies FBIO Competitors SABS Competitors CRIS Competitors BOLT Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTX) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access